Although the development of targeted therapeutic strategies blocking TNF α, IL-6 receptor, T-cell co-stimulation blockade and B-cell depletion have provided meaningful clinical benefit to patients, a key unmet need in the management of RA is the prospective identification of patients who are likely to benefit from specific therapies. The gene discussed is TNF; the disease is rheumatoid arthritis.